KKR to Present at the Bank of America Merrill Lynch 2016 Future of Financials Conference

NEW YORK--(BUSINESS WIRE)-- KKR & Co. L.P. (NYSE: KKR) announced today that William J. Janetschek, Chief Financial Officer, and Craig Larson, Head of Investor Relations, will present at the Bank of America Merrill Lynch 2016 Future of Financials Conference on Wednesday, November 16, 2016 at 10:45AM ET.

A live audio webcast of the presentation will be available on the Investor Center section of KKR’s website at http://ir.kkr.com/kkr_ir/kkr_events.cfm. For those unable to listen to the live audio webcast, a replay will be available on the website shortly after the event.

Any questions regarding the webcast may be addressed to KKR’s Investor Relations group at [email protected].

ABOUT KKR

KKR is a leading global investment firm that manages investments across multiple asset classes including private equity, energy, infrastructure, real estate, credit and hedge funds. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world‐class people, and driving growth and value creation at the asset level. KKR invests its own capital alongside its partners' capital and brings opportunities to others through its capital markets business. References to KKR's investments may include the activities of its sponsored funds. For additional information about KKR & Co. L.P. (NYSE: KKR), please visit KKR's website at www.kkr.com and on Twitter @KKR_Co.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161102006417/en/

Kohlberg Kravis Roberts & Co. L.P.
Investor Relations:
Craig Larson, +1-877-610-4910 (U.S.) / +1-212-230-9410
[email protected]
Media:
Kristi Huller, +1-212-750-8300
[email protected]

Source: KKR & Co. L.P.

You May Also Be Interested In

• KKR & Co. (KKR) to Acquire $1.64B Student Housing Portfolio from BREIT (BX)
• Blackstone (BX) to Acquire Tropical Smoothie Cafe
• KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma